Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.65 |
| ▸ | STAT3 | P40763 | 1/20 | 0.65 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.65 |
| ▸ | GSK3B | P49841 | 2/20 | 0.50 |
| ▸ | CDC7 | O00311 | 1/20 | 0.48 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.48 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.48 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | FLT3 | P36888 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.44 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.44 |
| ▸ | CDK1 | P06493 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | MARK3 | P27448 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14574212 | 0.89 | KDM4E (0.63) | KDM4ESTAT3HIF1AGSK3BCDC7 | |
| SCHEMBL3387632 | 0.88 | PRKAA1 (0.60) | KDM4ESTAT3HIF1AGSK3BCDC7 | |
| SCHEMBL4793050 | 0.84 | KDM4E (0.65) | KDM4ESTAT3HIF1ACDC7PRKAA1 | |
| SCHEMBL4101185 | 0.84 | KDM4E (0.68) | KDM4ESTAT3HIF1AGSK3BGAA | |
| SCHEMBL4794844 | 0.83 | KDM4E (0.63) | KDM4ESTAT3HIF1AGSK3BCDC7 | |
| SCHEMBL7345855 | 0.83 | KDM4E (0.63) | KDM4ESTAT3HIF1AGSK3BCDC7 | |
| SCHEMBL1141823 | 0.83 | KDM4E (0.63) | KDM4ESTAT3HIF1AGSK3BCDC7 | |
| SCHEMBL4291226 | 0.83 | KDM4E (0.63) | KDM4ESTAT3HIF1AGSK3BCDC7 | |
| SCHEMBL4793264 | 0.83 | KDM4E (0.63) | KDM4ESTAT3HIF1ACDC7PRKAA1 | |
| SCHEMBL2536370 | 0.83 | KDM4E (0.63) | KDM4ESTAT3HIF1ACDC7PRKAA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021050688-A1 | COMPOUNDS AND USES THEREOF | X-CHEM, INC. (US) | 2021-03-18 | — | — | WO | disclosed |
| WO-2021050688-A1 | COMPOUNDS AND USES THEREOF | X-CHEM, INC. (US) | 2021-03-18 | — | — | WO | disclosed |
| US-9777020-B2 | Furo-3-carboxamide derivatives and methods of use | ABBVIE INC. (US) | 2017-10-03 | — | — | US | disclosed |
| EP-3097095-A1 | FURO-3-CARBOXAMIDE DERIVATIVES AND METHODS OF USE | AbbVie Inc. (US) | 2016-11-30 | — | — | EP | disclosed |
| EP-2613782-B1 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | MERCK SHARP & DOHME (US) | 2016-11-02 | — | — | EP | disclosed |
| EP-2613782-B1 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | MERCK SHARP & DOHME (US) | 2016-11-02 | — | — | EP | disclosed |
| US-9249125-B2 | Pyrazole derivatives as p38 MAP inhibitors | RESPIVERT LIMITED (GB) | 2016-02-02 | — | — | US | disclosed |
| US-9249125-B2 | Pyrazole derivatives as p38 MAP inhibitors | RESPIVERT LIMITED (GB) | 2016-02-02 | — | — | US | disclosed |
| US-9249125-B2 | Pyrazole derivatives as p38 MAP inhibitors | RESPIVERT LIMITED (GB) | 2016-02-02 | — | — | US | disclosed |
| WO-2015112754-A1 | FURO-3-CARBOXAMIDE DERIVATIVES AND METHODS OF USE | ABBVIE INC. (US) | 2015-07-30 | — | — | WO | disclosed |
| WO-2012030685-A2 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | SCHERING CORPORATION (US) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012030685-A2 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | SCHERING CORPORATION (US) | 2012-03-08 | — | — | WO | disclosed |
| US-20100173899-A1 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-07-08 | — | — | US | disclosed |
| EP-2152664-A1 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS | Brystol-Myers Squibb Company (US) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008157162-A1 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-24 | — | — | WO | disclosed |
| US-20060135516-A1 | 3-(Carbonyl) 1h-indazole compounds as cyclin dependent kinases (cdk) inhibitors | ASTEX TECHNOLOGY, LTD. (GB) | 2006-06-22 | — | — | US | disclosed |
| US-20060135589-A1 | 1h-Indazole-3-carboxamide compounds as cyclin dependent kinase (cdk) inhibitors | ASTEX TECHNOLOGY, INC. (GB) | 2006-06-22 | — | — | US | disclosed |
| EP-1534685-A1 | 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS CYCLIN DEPENDENT KINASES (CDK) INHIBITORS | Astex Technology Limited (GB) | 2005-06-01 | — | — | EP | disclosed |
| WO-2005014554-A1 | 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS MAPKAP KINASE MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2005-02-17 | — | — | WO | disclosed |
| WO-2004014864-A1 | 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS CYCLIN DEPENDENT KINASES (CDK) INHIBITORS | ASTEX TECHNOLOGY LIMITED (GB) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135516-A1 | 3-(Carbonyl) 1h-indazole compounds as cyclin dependent kinases (cdk) inhibitors | CCNI, CDK3, CDK2 | KDM4E 758/4885STAT3 1740/4885HIF1A 561/4885 |
| US-20060135589-A1 | 1h-Indazole-3-carboxamide compounds as cyclin dependent kinase (cdk) inhibitors | CCNC, CDK1, CDK7 | KDM4E 2124/4885STAT3 1197/4885HIF1A 285/4885 |
| US-20100173899-A1 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS | F11, TFPI, SERPINC1 | KDM4E 1645/4885STAT3 2662/4885HIF1A 3046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.